DV
Dividend Vision

LUCD — Lucid Diagnostics Inc

Lucid Diagnostics Inc (LUCD)

Total return is -91.8% over the past 4.8 years, 178.9 points behind SPY at 87.1%. Its deepest 1-year drawdown was 40.7%.

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company that develops tests for detecting esophageal precancer and cancer in patients with gastroesophageal reflux disease (GERD); its flagship product is the EsoGuard Esophageal DNA Test, which uses samples collected with the EsoCheck device to identify early-stage disease in at-risk patients. The company does not currently distribute income to shareholders. This security appeals primarily to investors seeking exposure to early-stage medical technology development rather than those focused on current income generation.

LUCD key facts

Asset type
Stock
Asset class
Equity
Inception date
10/14/2021
Last close
$0.97
Market cap
$184,914,848
Average volume
574639.0
Beta
1.067
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.34